These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 37989383)

  • 1. Are pharmacists on the front lines of the opioid epidemic? A cross-sectional study of the practices and competencies of community and hospital pharmacists in Punjab, Pakistan.
    Mubarak N; Zahid T; Rana FR; Ijaz UE; Shabbir A; Manzoor M; Khan N; Arif M; Naeem MM; Kanwal S; Saif-Ur-Rehman N; Zin CS; Mahmood K; Asgher J; Elnaem MH
    BMJ Open; 2023 Nov; 13(11):e079507. PubMed ID: 37989383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. "The gatekeepers in prevention": Community pharmacist perceptions of their role in the opioid epidemic.
    Vadiei N; Eldridge LA; Meyerson BE; Agley J
    Subst Abus; 2022; 43(1):319-327. PubMed ID: 34214407
    [No Abstract]   [Full Text] [Related]  

  • 3. Assessing pharmacists' knowledge, attitudes, and practices of opioid management within different patient populations.
    Martin SE; Hughes TD; Roller J; Ferreri SP
    J Am Pharm Assoc (2003); 2024; 64(2):414-421.e1. PubMed ID: 38049067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient, family members and community pharmacists' views of a proposed overdose prevention intervention delivered in community pharmacies for patients prescribed high-strength opioids for chronic non-cancer pain: An explorative intervention development study.
    Mercer F; Parkes T; Foster R; Steven D; McAuley A; Baldacchino A; Steele W; Schofield J; Matheson C
    Drug Alcohol Rev; 2023 Mar; 42(3):517-526. PubMed ID: 36165733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic Evaluation of State Policy Interventions Targeting the US Opioid Epidemic, 2007-2018.
    Lee B; Zhao W; Yang KC; Ahn YY; Perry BL
    JAMA Netw Open; 2021 Feb; 4(2):e2036687. PubMed ID: 33576816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Indian Health Service pharmacists engaged in opioid safety initiatives and expanding access to naloxone.
    Duvivier H; Gustafson S; Greutman M; Jangchup T; Harden AK; Reinhard A; Warshany K
    J Am Pharm Assoc (2003); 2017; 57(2S):S135-S140. PubMed ID: 28292501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in Pharmacists' Perceptions After a Training in Opioid Misuse and Accidental Overdose Prevention.
    Eukel HN; Skoy E; Werremeyer A; Burck S; Strand M
    J Contin Educ Health Prof; 2019; 39(1):7-12. PubMed ID: 30614959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Opioid overdose prevention through pharmacy-based naloxone prescription program: Innovations in health care delivery.
    Bachyrycz A; Shrestha S; Bleske BE; Tinker D; Bakhireva LN
    Subst Abus; 2017; 38(1):55-60. PubMed ID: 27164192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Community Pharmacist Utilization of Legislation That Allows Impact on the Opioid Crisis in the State of Minnesota: A Mixed-Methods Approach.
    Palombi L; Hawthorne AN; Lunos S; Melgaard K; Dahly A; Blue H
    J Pharm Pract; 2020 Dec; 33(6):799-808. PubMed ID: 30983492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient acceptance of naloxone resulting from targeted intervention from community pharmacists to prevent opioid misuse and accidental overdose.
    Skoy E; Werremeyer A; Steig J; Eukel H; Frenzel O; Strand M
    Subst Abus; 2021; 42(4):672-677. PubMed ID: 33044896
    [No Abstract]   [Full Text] [Related]  

  • 11. Stigma by Association: To what Extent is the Attitude Toward Naloxone Affected by the Stigma of Opioid Use Disorder?
    Adeosun SO
    J Pharm Pract; 2023 Aug; 36(4):941-952. PubMed ID: 35505618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Presence of opioid safety initiatives, prescribing patterns for opioid and naloxone, and perceived barriers to prescribing naloxone: Cross-sectional survey results based on practice type, scope, and location.
    Kohan LR; Elmofty D; Pena I; Liao C
    J Opioid Manag; 2021; 17(1):19-38. PubMed ID: 33735425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preparing pharmacists to increase naloxone dispensing within community pharmacies under the Pennsylvania standing order.
    Santa HM; Amirova SG; Ventricelli DJ; Downs GE; Nowalk AA; Pringle JL; Aruru M
    Am J Health Syst Pharm; 2021 Feb; 78(4):327-335. PubMed ID: 33336254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The opioid abuse and misuse epidemic: implications for pharmacists in hospitals and health systems.
    Cobaugh DJ; Gainor C; Gaston CL; Kwong TC; Magnani B; McPherson ML; Painter JT; Krenzelok EP
    Am J Health Syst Pharm; 2014 Sep; 71(18):1539-54. PubMed ID: 25174015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Routine opioid outcome monitoring in community pharmacy: Pilot implementation study protocol.
    Nielsen S; Kowalski M; Wood P; Larney S; Bruno R; Shanahan M; Lenton S; Dietze P; Green T; Murnion B; Ritter A
    Res Social Adm Pharm; 2019 Aug; 15(8):1047-1055. PubMed ID: 30396825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identifying barriers to dispensing naloxone: A survey of community pharmacists in North Carolina.
    Rudolph SE; Branham AR; Rhodes LA; Hayes HH; Moose JS; Marciniak MW
    J Am Pharm Assoc (2003); 2018; 58(4S):S55-S58.e3. PubMed ID: 30006187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Student pharmacists' attitudes, perceptions, and knowledge regarding opioid use, misuse, and overdose: Four years of data.
    Murnane KS; Augustine JM; Marshall LL
    Curr Pharm Teach Learn; 2022 Oct; 14(10):1222-1228. PubMed ID: 36283793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Public attitudes and beliefs about Virginia community pharmacists dispensing and administering naloxone.
    Haggerty LC; Gatewood SS; Goode JKR
    J Am Pharm Assoc (2003); 2018; 58(4S):S73-S77.e1. PubMed ID: 30006189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Naloxone for opioid overdose prevention: pharmacists' role in community-based practice settings.
    Bailey AM; Wermeling DP
    Ann Pharmacother; 2014 May; 48(5):601-6. PubMed ID: 24523396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opioid Misuse and Overdose: Changes in Pharmacist Practices and Outcomes.
    Eukel H; Steig J; Frenzel O; Skoy E; Werremeyer A; Strand M
    J Contin Educ Health Prof; 2020; 40(4):242-247. PubMed ID: 33284175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.